TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01443845
Drug: Roflumilast
Normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Roflumilast 500 µg, oral administration, once per day
Study: NCT03452189
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral vancomycin 250mg capsules
Study: NCT00141167
Drug: varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03381703
Drug: 14C-labeled YH12852
Normalized name: urea [14C]
DrugBank: Urea C-13 (DB09510)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 14C-labeled YH12852 administration
Study: NCT00807144
Drug: Tacrolimus (Kidney transplant maintenance immunosuppression)
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-release Tacrolimus 1 to 20mg daily in two divided doses to maintain trough drug levels 6-9ng/ml
Study: NCT00232349
Drug: galantamine
Normalized name: Galantamine
DrugBank: Galantamine (DB00674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: open label galantamine, dosed at 4-12 mg/b.i.d., with a target dose of 12 mg/b.i.d.
Study: NCT00002964
Drug: porfimer sodium
Normalized name: Porfimer Sodium
DrugBank: Porfimer sodium (DB00707)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00735072
Drug: Maraviroc
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose based on current medications in regimen: 150mg orally (PO) twice daily (BID) for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens.
Study: NCT02349503
Drug: NBI-77860
Normalized name: NBI-98782
DrugBank: NBI-98782 (DB16905)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01437605
Drug: MAGE-A3 ASCI injections without Poly IC:LC
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAGE-A3 ASCI injections without Poly IC:LC as outlined in Detailed Description
Study: NCT01437605
Drug: MAGE-A3 ASCI injections with Poly IC:LC
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAGE-A3 ASCI injections with Poly IC:LC as outlined in Detailed Description
Study: NCT01112670
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: sitagliptin 100 mg x 1 dose
Study: NCT01112670
Drug: atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: atorvastatin 40 mg x 5 doses
Study: NCT00002852
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT00002852
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02553161
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Youth in the MED condition will be given the USFDA approved antidepressant, escitalopram for the treatment of depression or anxiety in youth and follow a standard dose titration schedule of 5 mg/day for 1 week, 10mg/day for 1 week, then with a target dose of 20-30 mg/day by 4 weeks. Titration will be no faster than 5mg/week. This titration guideline was drawn from the escitalopram package insert for pediatric dosing, which states that target doses may be achieved by 4 weeks.
Study: NCT04033107
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive intravenous Vitamin C injection (dose: 1.5g/kg, D1-3, every 2 weeks), treatment termination when the disease progress is confirmed.
Study: NCT04033107
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will orally take metformin 4g daily.
Study: NCT01405807
Drug: Alemtuzumab
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Alemtuzumab will be administered on Day 1 and Day 2 at 0 and 6 months
Study: NCT02250118
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intrapleural Bevacizumab
Study: NCT00134069
Drug: sorafenib tosylate
Normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00134069
Drug: cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT00134069
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03192215
Drug: Apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 5 mg by mouth twice daily (2.5 mg for subjects meeting standard criteria for an adjusted dose).
Study: NCT03192215
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 81 mg by mouth once daily.
Study: NCT02342782
Drug: Carmustine
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02342782
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02342782
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02342782
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01307267
Drug: PF-05082566
Normalized name: PF-05082566
DrugBank: Utomilumab (DB15113)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous, Dose escalation, once per month
Study: NCT01307267
Drug: rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous, 375 mg/m2, once per week for 4 weeks
Study: NCT01307267
Drug: PF-05082566
Normalized name: PF-05082566
DrugBank: Utomilumab (DB15113)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV, Dose escalation, once per month
Study: NCT02273544
Drug: Asasantin ER (new formulation - low)
Normalized name: Afsantin
DrugBank: Wormwood (DB14291)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02273544
Drug: Asasantin ER (new formulation - medium)
Normalized name: Afsantin
DrugBank: Wormwood (DB14291)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02273544
Drug: Asasantin ER (new formulation - high)
Normalized name: Afsantin
DrugBank: Wormwood (DB14291)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01305252
Drug: treprostinil inhalations
Normalized name: treprostinil Inhalation Solution
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treprostinil inhalation QID starting at 3 breaths per inhalation \& gradually increasing to 9 breaths. Each breath provides approximately 6mcg of treprostinil.
Study: NCT01305252
Drug: tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tadalafil 20mg QD PO increasing to 40mg QD as tolerated
Study: NCT03278925
Drug: Defined Green Tea Catechin Extract
Normalized name: green tea extract
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT00637585
Drug: Fexofenadine
Normalized name: Fexofenadine
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00252278
Drug: atomoxetine
Normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02034916
Drug: talazoparib
Normalized name: TALAZOPARIB
DrugBank: Talazoparib (DB11760)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00203216
Drug: levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daily dose of open label levatiracetam was 3000 mg. or maximally tolerated dose. (Maximum daily dose: 3000 mg. Minimum daily dose allowed for study participation:1000 mg)
Study: NCT00729560
Drug: Flutamide
Normalized name: Flutamide
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 250 mg twice daily for 4 weeks
Study: NCT04440085
Drug: Midodrine Hydrochloride
Normalized name: Midodrine Hydrochloride
DrugBank: Midodrine (DB00211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients become standard care resuscitation treatment using liquids and vasoactive drugs in order to get a median arterial pressure ≥ 65 mmHg. Midodrine will be administered according to the evolution of the patient's mean pressure.
Study: NCT00267657
Drug: Reserpine
Normalized name: Reserpine
DrugBank: Reserpine (DB00206)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03570437
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 80 mg/m2 on three days in a 28 day cycle (with 6 cycles)
Study: NCT03570437
Drug: Cediranib
Normalized name: cediranib
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg per day
Study: NCT03570437
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib tablets, 300 mg twice-daily
Study: NCT00238797
Drug: Gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02010944
Drug: solifenacin succinate
Normalized name: Solifenacin Succinate
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT02010944
Drug: mirabegron
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT00634075
Drug: omega-3-fatty acids (Omegaven)
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The enrolled patients will be randomized to receive either supplementation of fish oil-based lipid emulsion (10 % Omegaven) as group 1 or placebo (0.9% Normal Saline) as group 2 via a central venous catheter within 24 hours after ICU admission, 100 ml daily for 5 days, respectively.
Study: NCT00397475
Drug: Colecalciferol
Normalized name: colecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01972724
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone tablets
Study: NCT01972724
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin as prescribed in clinical practice
Study: NCT00536640
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg per os, given daily until tumor progression
Study: NCT00536640
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15mg/kg i.v. on day 1 (three-week cycle) until tumor progression
Study: NCT00536640
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1250 mg/2 i.v. on day 1 and day 8 (three-week cycle) until tumor progression for a maximum of 6 cycles
Study: NCT00536640
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 mg/m2 i.v. on day 1 (three-week cycle) until tumor progression for a maximum of 6 cycles. (The administration of 40 mg/2 Cisplatin on day 1 and day 8 is also possible)
Study: NCT01109498
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral, 2 g/day, day -3 till week 12
Study: NCT01109498
Drug: cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, 3 mg/kg/day, day -3 till week 12
Study: NCT01721434
Drug: Levosimendan
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02021006
Drug: nitrofurantoin
Normalized name: Nitrofurantoin
DrugBank: Nitrofurantoin (DB00698)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs~Physicians can chose one the following schedules:~* nitrofurantoin 1.5-2 mg/kg per day~* amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)~* cefixime 2 mg/kg per day~* trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)
Study: NCT01265173
Drug: Cefotaxime
Normalized name: Cefotaxime
DrugBank: Cefotaxime (DB00493)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 g
Study: NCT01265173
Drug: Ceftriaxone
Normalized name: Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 g
Study: NCT01265173
Drug: Ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg
Study: NCT02021006
Drug: Amoxicillin-Potassium Clavulanate Combination
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs~Physicians can chose one the following schedules:~* nitrofurantoin 1.5-2 mg/kg per day~* amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)~* cefixime 2 mg/kg per day~* trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)
Study: NCT02021006
Drug: Trimethoprim/sulfamethoxazole
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs~Physicians can chose one the following schedules:~* nitrofurantoin 1.5-2 mg/kg per day~* amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)~* cefixime 2 mg/kg per day~* trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)
Study: NCT02021006
Drug: Cefixime
Normalized name: Cefixime
DrugBank: Cefixime (DB00671)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs~Physicians can chose one the following schedules:~* nitrofurantoin 1.5-2 mg/kg per day~* amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)~* cefixime 2 mg/kg per day~* trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)
Study: NCT03960398
Drug: Iatrogenic disease impact on emergency consultations
Normalized name: IMPACT
DrugBank: Topramezone (DB14826)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Determination of the proportion of emergency consultations linked to iatrogenic diseases
Study: NCT00749749
Drug: Bupivacaine Collagen Sponge (CollaRx Bupivacaine Implant)
Normalized name: bupivacaine Drug Implant
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The bupivacaine collagen sponge contains 70mg Type I bovine collagen and 50mg bupivacaine hydrochloride
Study: NCT00002919
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002919
Drug: vinblastine sulfate
Normalized name: Vinblastine Sulfate
DrugBank: Vinblastine (DB00570)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01897259
Drug: Prolotherapy
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects participating in the prolotherapy group will recieve 1 cc 50% Dextrose and Sodium Morrhuate 1 cc injections.
Study: NCT03598140
Drug: Sildenafil Citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil 60mg once (Group 1) or daily for 2 weeks (Group 2)
Study: NCT02168660
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3, liquid formulation, 5000 IU/mL.
Study: NCT02047708
Drug: Zibotentan
Normalized name: Zibotentan
DrugBank: Zibotentan (DB06629)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective endothelin-A antagonist
Study: NCT01367483
Drug: IV methylnaltrexone (MNTX)
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01373398
Drug: EO9(Apaziquone)
Normalized name: Apaziquone
DrugBank: Apaziquone (DB12593)
Approvals — FDA: no, EMA: no, PMDA: no
Description: immediate instillation after TURBT + 6 weekly instillation 4mg/mL Apaziquone
Study: NCT00648349
Drug: Rabeprazole Sodium Delayed-Release Tablets 20 mg
Normalized name: rabeprazole sodium Delayed Release Oral Tablet
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mg, single dose fasting
Study: NCT00681525
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One 80 mg tablet of atorvastatin QD for 10 days
Study: NCT00681525
Drug: Ezetimibe
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One ezetimibe 10 mg tablet QD for 10 days
Study: NCT02658240
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ropivacaine 300 mg and 0.5 mg epinephrine diluted to 60 mL
Study: NCT02918279
Drug: Liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered once daily subcutaneously (s.c., under the skin)
Study: NCT01190007
Drug: Caduet
Normalized name: Caduet
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One Caduet tablet will be administered once daily after breakfast, in principle, for 52 weeks
Study: NCT00098553
Drug: everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01291615
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800mg/m2 - 1000mg/m2, day 1 every 3 weeks. day 1, 15 every 4 weeks. day 1, 8 every 3 weeks. day 1, 8, 15, every 4 weeks
Study: NCT01291615
Drug: S-1
Normalized name: LIS-1
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: S-1 40mg/day - 120mg/day (depend on body surface area) day 1-14, every 3 weeks day 1-28, every 6 weeks.
Study: NCT00666276
Drug: linezolid (Zyvox)
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zyvox Tablets 600mg, Zyvox Injection 600mg Dosage, Frequency: According to Japanese Package Insert, In adults, administer usually 600mg of linezolid twice daily (q 12 hours) for a total daily dose of 1200 mg.~Duration: According to the protocol of A5951142, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 8 weeks after the first administration.
Study: NCT01296191
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One drop 4 times daily for 3 days and one drop the day of sample collection
Study: NCT01296191
Drug: besifloxacin
Normalized name: Besifloxacin
DrugBank: Besifloxacin (DB06771)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One drop 4 times daily for 3 days and one drop on day of sample collection
Study: NCT01135511
Drug: Sodium Hyaluronate
Normalized name: sodium hyaluronate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ophthalmic topical solution, dosed 6 times/day, 8 weeks
Study: NCT01641224
Drug: Pinaverium
Normalized name: pinaverium
DrugBank: Pinaverium (DB09090)
Approvals — FDA: no, EMA: no, PMDA: no
Description: To test the effectiveness and safety of the formula for pain and diarrhea, we will randomly assign patients into one 3 groups: Pinaverium, TCM (Formula for pain and diarrhea) group, and placebo group, and treat them accordingly.
Study: NCT01641224
Drug: Radix codonopsitis
Normalized name: Valerianae radix
DrugBank: Valerian (DB13196)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radix codonopsitis (\~10-15g)
Study: NCT04496050
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The same drug will be used. In this study the same patients will be evaluated after the same dose of medication.
Study: NCT01368016
Drug: Nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single 6 mg dose of an experimental Nicotine Replacement Therapy (NRT), with a 36-hour washout between visits
Study: NCT01368016
Drug: Nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single 4 mg dose of a marketed Nicotine Gum, with a 36-hour washout between visits
Study: NCT01061151
Drug: Zidovudine (ZDV)
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg twice daily
Study: NCT01061151
Drug: Nevirapine (NVP): Antepartum Mothers
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg at onset of labor
Study: NCT01061151
Drug: Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]) tail
Normalized name: emtricitabine / tenofovir disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg/300 mg x 2 tablets at onset of labor or as soon as possible thereafter; 200 mg/300 mg orally each day after delivery for 7 days or the date of the Week 1 visit (up to 14 days), whichever is later.
Study: NCT01061151
Drug: Lamivudine-Zidovudine (3TC-ZDV)
Normalized name: lamivudine / zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg/300 mg twice daily
Study: NCT01061151
Drug: Lopinavir-ritonavir (LPV-RTV)
Normalized name: lopinavir / ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 400 mg/100 mg twice daily beginning at \>= 14 weeks gestation; 600 mg/150 mg twice daily beginning at \>= 28 weeks gestation or at next visit (during third trimester) through delivery; 400 mg/100 mg twice daily after delivery up to 14 days postpartum.
Study: NCT01641224
Drug: Radix curcumae
Normalized name: Curcumae Radix (Curcuma Longa)
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radix curcumae (\~10g)